Basic Mezavant Information

• INN (International Nonproprietary Name): Mesalazine or Mesalamine (also known as 5-aminosalicylic acid, 5‑ASA).
• Brand Names Available In Australia: Asacol; Asacol HD; Pentasa; Mezavant (Lialda in some markets); Salofalk; Rowasa (rectal forms; market dependent).
• ATC Code: A07EC02.
• Forms & Dosages: Delayed‑release tablets 400 mg and 800 mg (Asacol/Asacol HD), rectal enema and suppository forms available under various brands; common pack sizes 30/60/90 tablets.
• Manufacturers In Australia: Not specified in the supplied product information; global manufacturers include Tillotts Pharma, Zeria, Allergan and Meda Pharma.
• Registration Status In Australia: Not specified in the supplied product information; Asacol and other mesalazine products are registered in multiple international markets.
• OTC / Rx Classification: Prescription only (Rx) in the jurisdictions listed in the product information; not an over‑the‑counter medicine.

Major 2022–2025 Australian & Global Studies

Are recent trials changing how mesalazine is used?

Recent clinical trials and registry reports from 2022–2024 reinforce mesalazine as a mainstay for mild‑to‑moderate ulcerative colitis.

Randomised non‑inferiority trials and pooled meta‑analyses show induction remission signals cluster around benefit when total daily 5‑ASA dose is in the 2.4–4.8 g range.

Studies comparing once‑daily extended‑release and delayed‑release regimens with multiple daily dosing show improved adherence and similar efficacy for once‑daily products.

Rectal mesalazine remains highest yield for distal colitis and proctitis according to multiple trials and guideline summaries.

Australian cohort and registry analyses through 2023–24 highlight real‑world adherence gaps that blunt treatment effectiveness.

Practical trials show switching stable patients to once‑daily Mezavant/Lialda‑style regimens or Asacol delayed‑release formulations improves persistence in many community settings.

Asacol and similar mesalazine tablets appear repeatedly as trial comparators because of their established delayed‑release profile and recognised safety record.

Main Outcomes

What did the trials actually find?

Induction of remission rates cluster around clinically meaningful differences versus placebo when daily doses total 2.4–4.8 g, supporting product information dosing ranges.

Maintenance studies confirm lower relapse rates on 1.6–2.4 g daily compared with placebo in patients who achieved remission.

Once‑daily extended‑release formulations deliver similar efficacy with better adherence than thrice‑daily regimens in several head‑to‑head and pragmatic studies.

The combination of oral and rectal mesalazine for distal disease shows superior outcomes compared with oral therapy alone in multiple trials.

Safety Observations (TGA Reports)

Are there safety signals to watch for?

TGA and international regulator summaries continue to emphasise rare renal adverse events and hypersensitivity reactions with mesalazine.

Guidance remains to check baseline renal function and to monitor creatinine periodically during therapy.

Reports of interstitial nephritis are rare but clinically significant, and clinicians are advised to stop mesalazine if renal impairment develops.

Post‑market data reiterate that systemic allergic reactions, worsening colitis or chest pain require urgent medical review and drug cessation where appropriate.

Layman’s Explanation

How does mesalazine help someone with ulcerative colitis?

Mesalazine works by delivering an anti‑inflammatory medicine directly to the lining of the colon where the disease is active.

That local action helps calm inflammation without sending large amounts of drug into the bloodstream, which reduces some side effects.

Products such as Asacol use a delayed‑release coating so the tablet passes through the stomach and releases 5‑ASA in the terminal ileum and colon for a topical effect.

Scientific Breakdown

What is the pharmacology behind 5‑ASA?

Mesalazine inhibits prostaglandin and leukotriene synthesis and downregulates inflammatory mediators in the mucosa, contributing to reduced bowel inflammation.

It also scavenges reactive oxygen species and modulates local cytokine activity in the colonic mucosa.

Formulation technology matters because coatings and release platforms determine where along the gut the active drug is delivered.

Pharmacokinetics And Formulation Specifics

What happens to the drug in the body?

Systemic absorption of mesalazine is minimal when released in the colon, and metabolites are primarily acetylated and renally excreted.

Enteric or pH‑dependent coatings delay release until the pH approximates 7 in the ileocaecal region, helping target colonic disease.

Extended‑release formulations broaden distribution along the colon and can permit once‑daily dosing.

Renal clearance is the main route of elimination for metabolites, so renal impairment affects safety and dosing considerations.

Australian Approvals (TGA‑Listed, PBS Inclusion)

Is mesalazine registered here and subsidised?

Product information supplied lists Asacol and related mesalazine products as registered in multiple international markets, but specific Australian TGA registrations for each brand are not specified in the provided data.

PBS listing status varies by brand, strength and indication and should be checked in the current PBS Schedule and Authority requirements for subsidy eligibility.

Notable Off‑Label Trends In Australian Practice

How do Australian clinicians use mesalazine beyond approvals?

Clinicians sometimes use mesalazine for pouchitis prophylaxis or mild postoperative inflammation despite limited supporting evidence.

Use for Crohn’s disease is uncommon because efficacy is less well established than for ulcerative colitis.

Rectal mesalazine remains widely used and considered standard for proctitis or distal colitis.

In rural practice, prescribers often favour once‑daily options to improve adherence and reduce frequent pharmacy visits.

General Dosing

What are the usual dosing approaches?

Induction of remission in mild‑to‑moderate active ulcerative colitis generally uses 2.4–4.8 g/day orally in divided doses or as approved extended‑release regimens such as 800 mg tablets three times daily to reach target totals.

Maintenance dosing commonly sits at 1.6–2.4 g/day.

Children receive weight‑based dosing (50–75 mg/kg/day divided), and Asacol 400 mg is approved from 5 years upward in the provided information.

Condition‑Specific Dosing (PBS Recommendations)

How are doses adjusted for disease patterns?

For distal colitis or proctitis, adding rectal mesalazine to oral therapy improves response and is commonly recommended.

Severe flares may require doses at the higher end of 4.8 g/day or combined topical therapy under specialist supervision.

PBS items sometimes require authority prescriptions with criteria for dose and indication, so prescribers and pharmacists should confirm current PBS rules before issuing subsidised supplies.

Contraindications (Australian Guidelines)

Who should not take mesalazine?

Absolute contraindications include known hypersensitivity to mesalazine/mesalamine, aspirin, sulfasalazine or other salicylate‑containing agents, severe renal impairment, or a previous severe renal reaction to 5‑ASA.

Known allergy to tablet excipients is also an absolute contraindication.

Relative contraindications include history of kidney stones, liver impairment, severe GI obstruction and caution in pregnancy or breastfeeding where benefits must outweigh risks.

Adverse Effects (Post‑Market Pharmacovigilance)

What side‑effects are commonly seen and which are rare but serious?

Common mild adverse effects include headache, nausea, abdominal pain, diarrhoea, arthralgia and fatigue.

Moderate or rare events include worsening colitis, systemic hypersensitivity (rash, fever), renal dysfunction including interstitial nephritis, and rare cardiac symptoms such as chest pain or shortness of breath.

TGA communications emphasise baseline creatinine and periodic renal monitoring, and immediate review if renal function falls or systemic allergic signs appear.

Food Interactions (Alcohol, Coffee, Diet In Australia)

Do you need to avoid any foods while taking mesalazine?

No specific food interactions are established, and mesalazine may be taken with or without food.

Avoid excessive alcohol intake if there is coexisting liver disease or when taking other hepatotoxic medicines.

In hot Australian climates, managing hydration is important if diarrhoea occurs.

Drug Combinations To Avoid (TGA Safety Alerts)

Which medicines increase risk when combined with mesalazine?

Avoid or monitor co‑administration with nephrotoxic drugs such as NSAIDs, certain antibiotics and aminoglycosides, which can increase renal risk.

ACE inhibitors may also raise renal vigilance requirements when used with mesalazine.

Combining mesalazine with other salicylates can increase hypersensitivity risk.

Azathioprine or 6‑mercaptopurine are used clinically alongside mesalazine but require specialist monitoring for additive toxicity and interaction potential.

Australian Survey Data

What do Australian patients say about mesalazine?

Surveys and registries to 2024 show adherence is a major determinant of clinical outcome in ulcerative colitis treated with mesalazine.

Many patients report improved quality of life when on effective 5‑ASA regimens, especially when dosing frequency is simplified to once daily.

Cost, side‑effects and the perceived delay to benefit (often several weeks) are frequent patient concerns.

Rural patients commonly raise access and repeat prescription logistics as barriers to persistence.

Forum And Pharmacy Trends

What are pharmacists hearing in the community?

Community pharmacists routinely counsel on adherence, missed doses and the need for renal monitoring while patients remain on mesalazine therapy.

Online forums show frequent patient questions about brand substitution and cost, and pharmacists often clarify differences between Asacol, Pentasa, Mezavant and generics.

Pharmacies such as Chemist Warehouse, Priceline and TerryWhite commonly stock mesalazine brands and help patients navigate PBS eligibility and authority scripts.

National Pharmacy Chains

Where can patients collect mesalazine?

Major national chains and community pharmacies generally stock mesalazine brands and generics in standard pack sizes.

Availability of specific strengths (Asacol 400 mg, Asacol HD 800 mg) and pack sizes can vary by store and region.

Online Pharmacy Growth And Telehealth E‑Scripts

How has online access changed things?

Growth in telehealth and e‑scripts has improved access, particularly for remote patients who previously needed repeated in‑person visits for authority scripts and repeats.

In our online pharmacy, mezavant is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Online pharmacies ship nationally, and packaging for summer heat is important to protect tablet integrity during transport.

PBS Vs Private Cost Comparisons

How much will mesalazine cost me?

PBS subsidy can significantly reduce out‑of‑pocket costs when the prescribed item and patient meet the criteria.

Private payers face variable prices across brands and generics, and many patients opt for generics to reduce cost.

Pharmacists can check the current PBS Schedule for exact prices, concession rates and authority requirements.

Comparison Of PBS And Non‑PBS Options

Which formulations are commonly considered?

Pentasa uses a sustained‑release mechanism and distributes drug more proximally in the small bowel.

Mezavant or Lialda use extended‑release technology and are often favoured for once‑daily dosing to improve adherence.

Salofalk offers multiple formulations including granules and rectal options helpful for tailoring to distal disease.

Rectal forms such as Rowasa are more common in some markets and may not be subsidised on the PBS.

Pros And Cons Checklist

How to choose a formulation in practice?

Asacol (Delayed‑Release): Pros — targeted colonic delivery and established safety record.

Pentasa (Sustained‑Release): Pros — broader small‑bowel coverage, useful if proximal involvement suspected.

Mezavant/Lialda (Extended‑Release): Pros — once‑daily dosing can improve adherence.

Generics: Pros — lower cost; Cons — varying excipients and occasional patient confusion with brand names.

Formulation choice should be guided by disease location, likelihood of adherence and PBS availability, in consultation with the treating gastroenterologist and pharmacist.

TGA Approval Framework

How are mesalazine products regulated?

Mesalazine products are prescription medicines evaluated by the Therapeutic Goods Administration for quality, safety and efficacy.

Product information and approved indications mirror international regulators and are essential references for prescribers.

PBS Subsidy Process

How do medicines get on the PBS?

Listing on the PBS requires a PBAC submission demonstrating cost‑effectiveness and clinical need.

Items listed may carry Authority requirements such as specialist initiation or indication criteria, and listings can change periodically.

Practitioners should confirm current PBS Schedule entries before prescribing to ensure subsidy eligibility and correct authority procedure.

Consolidated FAQ

Is Asacol on the PBS?

PBS coverage depends on brand, strength and eligibility criteria; check the current PBS Schedule or ask your pharmacist for the latest listing and any authority requirements.

How long until I feel better?

Some patients notice improvement within 2–4 weeks, but optimal induction often takes 6–8 weeks and up to the full induction course specified in product information.

Can I take Asacol in pregnancy or while breastfeeding?

Use only if the potential benefit outweighs risk; discuss treatment with an obstetrician or gastroenterologist and monitor appropriately.

What if I miss a dose?

Take the missed dose as soon as you remember unless it is near the time for the next dose; do not double up.

Do I need blood tests?

Baseline renal function and periodic creatinine monitoring are recommended because of the rare but important renal risks associated with mesalazine.

Visual Guide Suggestions

What visuals help patients understand mesalazine?

Suggested infographic elements include a PBS pricing flow chart that contrasts full price and concession copayments with the authority script pathway.

A distribution map showing urban pharmacy density versus rural access, overlaid with telehealth and e‑script reach, clarifies access for remote patients.

A formulation decision tree linking disease location to oral, rectal or combined therapy and showing induction versus maintenance dosing ranges is useful in clinic waiting rooms.

A safety checklist panel with baseline creatinine, monitoring intervals and red flags (rash, worsening colitis, reduced urine output) helps adherence to monitoring guidance.

Household Storage Under Australian Climate

How should mesalazine be stored at home?

Store tablets at room temperature between 15–30°C and protect them from moisture and direct sunlight.

Avoid storing medication in bathrooms or car gloveboxes during hot Australian summers because humidity and heat can degrade tablets.

For mail orders to rural areas in summer, ask your pharmacy for insulated packaging or expedited delivery to limit heat exposure.

Cold‑Chain Logistics For Pharmacies

Does mesalazine need refrigeration?

Mesalazine does not require cold‑chain transport, but pharmacies should store stock at controlled room temperature with humidity control and rotate stock by expiry.

Keep blister packs away from heat and moisture and counsel patients to store blister cards in a cool, dry place.

Pharmacies servicing remote clinics should maintain adequate stock levels and manage returns for short‑dated packs to avoid wastage.

Pharmacist Counselling Style In Australia

What should pharmacists tell patients when dispensing mesalazine?

Confirm the indication and exact formulation, including the strength (Asacol 400 mg versus Asacol HD 800 mg) and whether the patient is eligible for any PBS subsidy.

Briefly explain the mechanism as a topical anti‑inflammatory in the colon and set expectations about a several‑week time to benefit.

Emphasise adherence, missed dose rules (do not double up), and the need for baseline and periodic renal function tests.

Advise on storage in the Australian climate and offer help navigating cost or switching to a generic where appropriate.

National Health Authority Recommendations

Which national guidance should clinicians follow?

Refer to TGA product information and Australian gastroenterology guideline recommendations for induction and maintenance dosing, monitoring intervals and specialist referral triggers.

Pharmacists should liaise with specialists for complex situations such as pregnancy, renal impairment or refractory disease.

Consolidated Patient Counselling Checklist

• Confirm indication, formulation and PBS status.
• Explain expected timeline for benefit (weeks) and importance of adherence.
• Give safety advice: baseline creatinine and when to seek urgent review.
• Discuss missed dose rules and storage advice for the Australian climate.

Common Patient Questions Addressed

How quickly will stool frequency improve?

Symptom change varies, but many patients notice partial improvement within 2–4 weeks with full induction assessed at around 6–8 weeks.

What should trigger an urgent review?

New rash, fever, worsening bloody diarrhoea or reduced urine output are red flags that require immediate medical review and consideration of drug cessation.

Delivery Across Australia

Storage And Transport Final Notes

When shipping to remote areas, choose expedited or insulated packaging during hot months to preserve tablet integrity.

Deliveries should remain in original containers and be stored at room temperature on receipt.

Guidelines For Proper Use

What is the pharmacist’s practical approach at dispensing?

Confirm the product, advise on dosing and the likelihood of several weeks before full benefit, and clarify PBS or authority requirements for subsidised supply.

Ensure baseline renal tests are arranged if not already done, and provide clear instructions for missed doses and when to seek urgent review.

Where repeat prescribing is needed, discuss telehealth options and longer repeat supplies to improve adherence, especially for rural patients.

Final Safety Reminders

Stop mesalazine and seek medical review if renal function worsens, if new rash or systemic symptoms develop, or if bloody diarrhoea increases.

Keep regular monitoring appointments and check with your pharmacist or specialist if there is uncertainty about the best formulation for your disease location.

Where To Get Help

If you have questions about accessing mesalazine, PBS eligibility, or need help with repeats and e‑scripts, speak with your local pharmacist or specialist clinic.

Pharmacies can assist with authority scripts, substitution options between Asacol, Pentasa and mezavant‑style extended‑release products, and counselling on storage during Australian summers.